Bristol-Myers to pay $1.85B in cancer deal with Nektar
Nektar will receive $1 billion in cash upfront and Bristol-Myers will purchase about 8.28 million Nektar shares at $102.60 per share, or an equity stake of just under 5 percent of the company
Wednesday, February 14, 2018
Bristol-Myers to pay $1.85B in cancer deal with Nektar
Bristol-Myers to pay $1.85B in cancer deal with Nektar
Nektar will receive $1 billion in cash upfront and Bristol-Myers will purchase about 8.28 million Nektar shares at $102.60 per share, or an equity stake of just under 5 percent of the company
Related Posts:
Ivanka Trump closes fashion line to focus on helping her father- Facebook plans innovation hub in China despite tightening censorship
- Asian chipmakers' production plans in focus as super-cycle winds down
- Brussels, Greece among EU Brexit options for London insurance brokers: trade body
- Harley-Davidson's profit beats estimates, shares rally
0 comments:
Post a Comment